JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK/STAT and ROS-MAPK/NF-κB signalling pathways in acute graft-versus-host disease.

Yigeng Cao,Jiali Wang,Shan Jiang,Mengnan Lyu, Fei Zhao,Jia Liu,Mingyang Wang,Xiaolei Pei,Weihua Zhai,Xiaoming Feng,Sizhou Feng,Mingzhe Han,Yuanfu Xu,Erlie Jiang

Clinical & translational immunology（2023）

引用 1|浏览30

暂无评分

摘要

Ruxolitinib enhances PMN-MDSCs functions through JAK/STAT and ROS-MAPK/NF-κB signalling pathways. Monitoring frequencies and functions of MDSCs can help evaluate treatment responses to ruxolitinib.

查看译文

关键词

JAK/STAT pathway,ROS,acute graft‐versus‐host disease,myeloid‐derived suppressor cells

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要